ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC
ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.
Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors
September 26th 2023J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.
Dr Callahan on Commonly Used Imaging Modalities in Breast Cancer
August 31st 2023Rena D. Callahan, MD, discusses the range of metastatic imaging techniques available in breast cancer, the benefits of liquid biopsy, and the importance of looking for bone metastases in patients with metastatic breast cancer.
Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma
Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL.